Remarkable prognostic heterogeneity justifies subdividing high-risk gastrointestinal stromal tumors (GIST) of NIH consensus scheme into two different risk groups

被引：0
|
作者：
Li, CF
Huang, WW
Lin, CN
Lu, D
Huang, HY
机构：
[1] Chi Mei Fdn Med Ctr, Tainan, Taiwan
[2] Natl Cheng Kung Univ, Coll Med, Tainan 70101, Taiwan
[3] Chang Gung Mem Hosp, Kaohsiung, Taiwan
来源：
LABORATORY INVESTIGATION | 2006年 / 86卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
509
引用
收藏
页码：112A / 112A
页数：1
相关论文
共 50 条
  • [21] Analysis of risk factors of gastrointestinal stromal tumors in different age groups based on SEER database
    Ge, Xin-Yu
    Lei, Li-Wang
    Ge, Fei
    Jiang, Xian
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2019, 54 (04) : 480 - 484
  • [22] The real world outcomes of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST).
    Rutkowski, Piotr
    Zietek, Marcin
    Cybulska-Stopa, Bozena
    Streb, Joanna
    Gluszek, Stanislaw
    Jankowski, Michal
    Lopacka-Szatan, Karolina
    Las-Jankowska, Manuela
    Hudziec, Piotr
    Klimczak, Anna
    Olesinski, Tomasz
    Switaj, Tomasz
    Kosela-Paterczyk, Hanna
    Bylina, Elzbieta
    Osuch, Czeslaw
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [23] Clinical outcomes and prognostic factors for patients with high-risk gastrointestinal stromal tumors treated with 3-year adjuvant imatinib
    Bang, Yeong Hak
    Ryu, Min-Hee
    Kim, Hyung-Don
    Lee, Hyung Eun
    Kang, Yoon-Koo
    INTERNATIONAL JOURNAL OF CANCER, 2022, 151 (10) : 1770 - 1777
  • [24] Analysis of reliability of different risk classifications for assessment of relapses of gastrointestinal stromal tumors (GIST) - the impact of primary tumor genotyping
    Bylina, Elzbieta
    Osuch, Czeslaw
    Rutkowski, Piotr
    ONCOLOGY IN CLINICAL PRACTICE, 2020, 16 (05): : 276 - 294
  • [25] Thymosin beta-4 overexpression correlates with high-risk groups in gastric gastrointestinal stromal tumors: A retrospective analysis by immunohistochemistry
    Sahin, Sevinc
    Ekinci, Ozgur
    Seckin, Selda
    Dursun, Ayse
    PATHOLOGY RESEARCH AND PRACTICE, 2017, 213 (09) : 1139 - 1143
  • [26] Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome
    Wen-Yi Zhao
    Jia Xu
    Ming Wang
    Zi-Zhen Zhang
    Lin Tu
    Chao-Jie Wang
    Hui Cao
    Zhi-Gang Zhang
    BMC Gastroenterology, 14
  • [27] Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome
    Zhao, Wen-Yi
    Xu, Jia
    Wang, Ming
    Zhang, Zi-Zhen
    Tu, Lin
    Wang, Chao-Jie
    Cao, Hui
    Zhang, Zhi-Gang
    BMC GASTROENTEROLOGY, 2014, 14
  • [28] Identification of key genes related to high-risk gastrointestinal stromal tumors using bioinformatics analysis
    Jin, Shuan
    Zhu, Wenhua
    Li, Jun
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 14 : S243 - S247
  • [29] Long-term adjuvant therapy for high-risk gastrointestinal stromal tumors in the real world
    Toshirou Nishida
    Shinsuke Sato
    Masato Ozaka
    Yujiro Nakahara
    Yoshito Komatsu
    Masato Kondo
    Haruhiko Cho
    Seiichi Hirota
    Tatsuo Kagimura
    Yukinori Kurokawa
    Yuko Kitagawa
    Gastric Cancer, 2022, 25 : 956 - 965
  • [30] Effect of the imatinib treatment regimen on the postoperative prognosis of patients with high-risk gastrointestinal stromal tumors
    Li, Yan-Shu
    Li, Wei
    Zeng, Qing-Sheng
    Fu, Wei-Hua
    ONCOTARGETS AND THERAPY, 2019, 12 : 4713 - 4719
12345